Skip Navigation
Department of Health and Human Services www.hhs.gov
 
Slide Tray
0 slides

Return to Slide Library

Slides

Add Presentation to Slide Tray Presentation:

Angiotensin-Converting Enzyme Inhibitors (ACEIs), Angiotensin II Receptor Antagonists (ARBs), or Direct Renin Inhibitors (DRI) for Adults With Hypertension

Slide: 9 of 16

Number of Studies Evaluating Various Treatment Options

The 110 included direct comparator articles reported on 100 distinct studies. Seventy-four of these were randomized controlled trials (RCTs), 4 were nonrandomized  controlled trials, 16 were retrospective cohort studies, 3 were prospective cohort studies, and 1 study each were a cross-sectional cohort, a case-control study, and a retrospective chart review. This table describes the number of studies that evaluated various possible treatment comparisons. As this table illustrates, enalapril was by far the most frequently studied ACEI (30 studies) and losartan the most frequently studied ARB, followed by telmisartan. The most commonly studied treatment comparison was the generic “ACEIs” versus “ARBs” (20 studies), followed by enalapril versus losartan (13 studies). Other treatment comparisons were fairly sparsely represented. Only three studies compared the DRI aliskiren with either an ACEI (ramipril) or ARB (losartan).